Venous Thromboembolism in Cancer Patients on Simultaneous and Palliative Care
Autor: | Silvia Riondino, Mario Roselli, Fiorella Guadagni, Girolamo Del Monte, Vincenzo Formica, Patrizia Ferroni |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2020 |
Předmět: |
Cancer Research
medicine.medical_specialty Palliative care medicine.drug_class venous thromboembolism Disease Review 030204 cardiovascular system & hematology simultaneous care lcsh:RC254-282 Settore MED/06 03 medical and health sciences 0302 clinical medicine Antithrombotic medicine Thrombus Intensive care medicine integrated care business.industry Anticoagulant Cancer medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Integrated care Oncology 030220 oncology & carcinogenesis thromboprophylaxis business Venous thromboembolism |
Zdroj: | Cancers Cancers, Vol 12, Iss 1167, p 1167 (2020) |
ISSN: | 2072-6694 |
Popis: | Simultaneous care represents the ideal integration between early supportive and palliative care in cancer patients under active antineoplastic treatment. Cancer patients require a composite clinical, social and psychological management that can be effective only if care continuity from hospital to home is guaranteed and if such a care takes place early in the course of the disease, combining standard oncology care and palliative care. In these settings, venous thromboembolism (VTE) represents a difficult medical challenge, for the requirement of acute treatments and for the strong impact on anticancer therapies that might be delayed or, even, totally discontinued. Moreover, cancer patients not only display high rates of VTE occurrence/recurrence but are also more prone to bleeding and this forces clinicians to optimize treatment strategies, balancing between hemorrhages and thrombus formation. VTE prevention is, therefore, regarded as a double-edged sword. Indeed, while on one hand the appropriate use of antithrombotic agents can reduce VTE occurrence, on the other it significantly increases the bleeding risk, especially in the frail patients who present with multiple co-morbidities and poly-therapy that can interact with anticoagulant drugs. For these reasons, thromboprophylaxis should start while active cancer treatment is ongoing, according to a simultaneous care model in a patient-centered perspective. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |